StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3036% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Alpine Immune Sciences — Total liabilities by Year

Alpine Immune Sciences — Total liabilities ($M) ($M)

Vertex Pharmaceuticals Alpine Immune Sciences — Total liabilities: $51.9M in FY2023, down 51.6% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2023
51.9
Period ended Dec 31, 2023
Change on a year earlier
-51.6%
107 in FY2022
History
6 years
Since FY2018
Sources
6
Documents cited below

Where the FY2023 figure comes from

Source: SEC Filing ↗

Reported in SEC XBRL (CIK 0001626199 Alpine Immune Sciences).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAlpine Immune Sciences — Total liabilities ($M) ($M)Year on yearSource
FY2023Dec 31, 202351.9-51.6%SEC Filing ↗
FY2022Dec 31, 2022107-20.5%SEC Filing ↗
FY2021Dec 31, 2021135+64.8%SEC Filing ↗
FY2020Dec 31, 202081.9+232.8%SEC Filing ↗
FY2019Dec 31, 201924.6+139.5%SEC Filing ↗
FY2018Dec 31, 201810.3–SEC Filing ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Alpine Immune Sciences — Total liabilities ($M), annual FY2018–FY2023 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/alpine-liabilities

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.